Eli Lilly shares jump after EU panel backs expanded use of Jaypirca
Lilly’s stock rose sharply after the EU’s medicines committee recommended using Jaypirca (pirtobrutinib) in a broader adult population, a step that could expand the drug’s addressable market in Europe.